Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
trial exchanges : Nyse save search
Theriva™ Biologics Announces Positive Topline Data from Investigator Sponsored Phase 1 Trial of Intravitreal VCN-01 in Pediatric Patients with Refractory Retinoblastoma
Published: 2024-04-23 (Crawled : 11:00) - globenewswire.com
TOVX | News | $0.3769 -8.3% -1.83% 1.2M
|
Manufacturing
|
| O: 0.73%
H: 0.0%
C: 0.0%
vcn-01 positive topline trial
SNIPR Biome receives funding from CARB-X to support advancement of CRISPR-medicine SNIPR001 into clinical trials in haematological cancer patients
Published: 2024-04-22 (Crawled : 18:00) - biospace.com/
NVO | News | $128.64 2.7% -0.07% 3.7M
|
Health Technology
|
| O: -0.1%
H: 2.99%
C: 2.18%
snipr001 cancer trials funding
Health Canada Approves KEYTRUDA as a first-line treatment for adult patients with locally advanced unresectable or metastatic HER2-negative gastric or gastroesophageal junction (GEJ) adenocarcinoma
Published: 2024-04-19 (Crawled : 13:00) - biospace.com/
MRK | $126.88 -0.05% -0.13% 7.5M
|
Health Technology
|
| O: 0.22%
H: 0.37%
C: 0.1%
health treatment for canada advanced keytruda
Clinical Trials Matching Software Market Projected to Reach $832.56 million by 2030 - Exclusive Report by 360iResearch
Published: 2024-04-19 (Crawled : 04:00) - prnewswire.com
IBM | $182.19 0.16% 0.63% 5.9M
|
Technology Services
|
| O: 0.13%
H: 0.2%
C: -0.47%
report million software reach trials market
Phase 3 SELECT-GCA Study of Upadacitinib (RINVOQ®) Showed Positive Results in Patients With Giant Cell Arteritis
Published: 2024-04-18 (Crawled : 19:00) - biospace.com/
ABBV | News | $169.54 0.98% -0.91% 4.1M
|
Health Technology
|
| O: 0.75%
H: 0.0%
C: 0.0%
rinvoq positive cell results study
Ventus Therapeutics Announces Results from Phase 1 Clinical Trial of VENT-02, a Novel, Orally Administered, Brain-Penetrant NLRP3 Inhibitor
Published: 2024-04-17 (Crawled : 14:00) - biospace.com/
NVO | News | $128.64 2.7% -0.07% 3.7M
|
Health Technology
|
| O: 1.22%
H: 0.21%
C: -0.34%
vent-02 trial therapeutics results
Tirzepatide reduced sleep apnea severity by up to nearly two-thirds in adults with obstructive sleep apnea (OSA) and obesity
Published: 2024-04-17 (Crawled : 11:00) - biospace.com/
LLY | News | $745.69 1.96% -0.16% 2M
|
Health Technology
|
| O: 1.03%
H: 1.66%
C: -1.11%
obesity tirzepatide
SyntheticMR and SimonMed Expand Trials of Synthetic MRI Testing and Announce Upcoming Expansion of Synthetic Availability from SyntheticMR's SyMRI NEURO Software at SimonMed Facilities
Published: 2024-04-17 (Crawled : 09:00) - prnewswire.com
PHG | News | $21.01 1.94% 0.0% 2M
|
Health Technology
|
| O: -2.01%
H: 1.0%
C: 0.7%
software expansion trials
Teva’s New Real-World Evidence Presented at the 2024 AAN Annual Meeting Confirms Effectiveness and Patient Satisfaction for HD Chorea with the 4-week Titration Kit for AUSTEDO® (deutetrabenazine) Tablets
Published: 2024-04-16 (Crawled : 13:00) - biospace.com/
TEVA | $13.01 1.01% 0.0% 8.9M
|
Health Technology
|
| O: 0.23%
H: 0.23%
C: -1.28%
austedo for meeting
AviadoBio Announces First Patient Treated in ASPIRE-FTD Clinical Trial Evaluating AVB-101 for Frontotemporal Dementia with GRN Mutations
Published: 2024-04-15 (Crawled : 12:00) - biospace.com/
JNJ | News | $149.56 0.3% 0.0% 9.1M
|
Health Technology
|
| O: -0.04%
H: 0.0%
C: 0.0%
avb-101 first dementia for trial
Teva Confirms Efficacy and Safety of AJOVY® (fremanezumab) for the Prevention of Migraine With Results from Phase 3 Trial in China
Published: 2024-04-11 (Crawled : 23:00) - biospace.com/
TEVA | $13.01 1.01% 0.0% 8.9M
|
Health Technology
|
| O: -1.01%
H: 2.04%
C: 1.17%
ajovy for teva trial migraine china results
SMART trial one-year data demonstrates Medtronic Evolut™ TAVR platform as optimal treatment for severe aortic stenosis in patients with small annulus, which is primarily women
Published: 2024-04-07 (Crawled : 16:20) - prnewswire.com
MDT | $81.29 0.89% 0.0% 5.2M
|
Health Technology
| Email alert
Add to watchlist
EW | $87.75 0.91% 0.0% 2.7M
|
Health Technology
| Email alert
Add to watchlist
treatment for women smart trial platform
Contineum Dials Back Plans with $110M IPO to Fund Neuroinflammatory Trials
Published: 2024-04-05 (Crawled : 14:30) - biospace.com/
JNJ | News | $149.56 0.3% 0.0% 9.1M
|
Health Technology
|
| O: -1.84%
H: 0.0%
C: 0.0%
neuroinflammatory back trials
Merck Initiates Phase 3 Clinical Trial of MK-1084, an Investigational Oral KRAS G12C Inhibitor, in Combination with KEYTRUDA® (pembrolizumab) for First-Line Treatment of Certain Patients With Metastatic Non-Small Cell Lung Cancer
Published: 2024-04-04 (Crawled : 12:00) - biospace.com/
MRK | $126.88 -0.05% -0.13% 7.5M
|
Health Technology
|
| O: 0.24%
H: 0.08%
C: -2.42%
mk-1084 keytruda lung merck cancer cell treatment trial
ADC Therapeutics Announces Updates on LOTIS-7 Clinical Trial Evaluating ZYNLONTA® in Combination with Glofitamab or Mosunetuzumab in Patients with Relapsed/Refractory B-cell Non-Hodgkin Lymphoma
Published: 2024-04-04 (Crawled : 11:00) - globenewswire.com
ADCT | $4.97 6.2% 2.21% 400K
|
Health Technology
|
| O: 0.68%
H: 11.71%
C: 6.08%
zynlonta trial therapeutics
REJOICE-Ovarian01 Phase 2/3 Trial of Raludotatug Deruxtecan Initiated in Patients with Platinum-Resistant Ovarian Cancer
Published: 2024-04-03 (Crawled : 13:00) - biospace.com/
MRK | $126.88 -0.05% -0.13% 7.5M
|
Health Technology
|
| O: 0.13%
H: 0.0%
C: 0.0%
cancer trial initiated
LUXH FINAL DEADLINE ALERT: ROSEN, NATIONAL TRIAL LAWYERS, Encourages LuxUrban Hotels, Inc. Investors to Secure Counsel Before Important April 12 Deadline in Securities Class Action - LUXH
Published: 2024-04-02 (Crawled : 00:00) - prnewswire.com
LUXH | $0.8797 -5.64% -5.98% 150K
|
|
| O: -0.71%
H: 2.86%
C: -2.86%
BCDRF | $4.978 -8.71% 100
|
Finance
|
| O: 3.9%
H: 4.33%
C: 4.33%
SHLS | $8.45 0.24% 0.24% 3.2M
|
|
| O: 0.19%
H: 2.0%
C: 0.84%
SAN | $4.99 2.68% -0.2% 11M
|
Finance
|
| O: 1.04%
H: 1.23%
C: 0.82%
deadline trial
Bristol Myers Squibb Provides Update on the First Phase 3 YELLOWSTONE Trial Evaluating Oral Zeposia (ozanimod) in Patients with Moderate to Severe Active Crohn’s Disease
Published: 2024-03-28 (Crawled : 22:00) - biospace.com/
BMY | $48.99 -0.31% 0.0% 9.1M
|
Health Technology
|
| O: 0.26%
H: 2.03%
C: 1.57%
first disease active update trial
AEOVIAN PHARMACEUTICALS DOSES FIRST PARTICIPANTS IN PHASE 1 CLINICAL TRIAL, STRENGTHENS LEADERSHIP TEAM AND RAISES ADDITIONAL $50 MILLION FINANCING
Published: 2024-03-28 (Crawled : 13:00) - prnewswire.com
MS | News 0 d | $93.76 1.81% 0.12% 6.4M
|
Finance
|
| O: 0.27%
H: 1.05%
C: 0.44%
JAZZ | $109.685 0.79% 0.78% 380K
|
Health Technology
|
| O: 0.0%
H: 0.85%
C: -0.07%
first million pharmaceuticals
Global $4.1 Billion Clinical Trial Supplies Market Report 2024-2034 - Emerging Markets Catalyzing Growth in Clinical Trial Supplies
Published: 2024-03-26 (Crawled : 17:00) - prnewswire.com
JNJ | News | $149.56 0.3% 0.0% 9.1M
|
Health Technology
|
| O: 0.01%
H: 0.0%
C: 0.0%
ICLR | News | $306.16 2.76% 2.68% 860K
|
Health Technology
|
| O: 0.46%
H: 0.65%
C: -0.43%
report global trial growth market
Gainers vs Losers
| 78% | 22% |
Top 10 Gainers
MTTR | News 4 | $4.6 164.37% 62.17% 28M
|
AGBA | $2.94 135.2% 57.48% 66M
|
Finance
EDBL | News | $6.46 71.81% 41.8% 2M
|
MTC | $2.25 44.23% 30.67% 6M
|
Technology Services
OPRT | News | $3.175 41.11% 29.13% 12M
|
Finance
SHIM | $3.05 35.56% 26.23% 1.1M
|
HKIT | $1.345 31.86% 24.16% 390K
|
Technology Services
ABVC | $1.36 30.77% 23.53% 7.4M
|
Wholesale Trade
OST | $0.512 28.0% 21.88% 290K
|
POET | $1.59 27.2% 21.38% 4.2M
|
Manufacturing
Your saved searches
Save your searches and get alerts when important news are released.